A Phase 2 interventional study of Dexketoprofen Trometamol and Dexketoprofen Trometamol in Pain, sponsored by Menarini Group. Completed at 16 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-08-12.
Sponsored by Menarini Group · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dexketoprofen in Pain — 1 open to participants now, 1 under way, none of them phase 3. dexketoprofen · Pain.
Among the 10 studies testing dexketoprofen in Pain, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 2, and was the 1st registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →1 of the 10 studies testing dexketoprofen in Pain is open now, in 1 country. Recruiting first, the newest first:
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 745 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 10 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 8 most frequent:
Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Menarini Group has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing dexketoprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single component in comparison to placebo on moderate to severe pain following impacted third mandibular molar tooth extraction. Ibuprofen will be used as an active control to validate the pain model.
The aim of this study is to develop a combination of Dexketoprofen Trometamol (DKP.TRIS) and Tramadol Hydrochloride (TRAM.HCl) for the treatment of acute moderate to severe pain, based on the rationale that more than one drug is necessary in most patients suffering of acute and chronic pain, particularly of moderate to severe intensity.
DKP.TRIS and TRAM.HCl have different mechanisms of action, therefore their combination is expect to result in an additive or synergistic analgesia, thus allowing a decrease in the required doses of the individual agents, and consequently a reduced risk of adverse events In this study, patients who present moderate to severe pain after impacted third mandibular molar tooth extraction will be randomised to a total of 10 treatment arms including 4 combinations of DKP.TRIS + TRAM.HCl, the four corresponding single treatments, placebo and ibuprofen. Treatment administration will be followed by a 24-hour pain and analgesic effect assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients meeting ALL the following criteria will be eligible for entry into the study:
At randomisation (after surgery):
No intake of analgesics (including prescription and over the counter drugs) within 24h prior to the surgery.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Ibuprofen
Drug: Tramadol Hydrochloride
Drug: Tramadol Hydrochloride
Drug: Dexketoprofen Trometamol
Drug: Dexketoprofen Trometamol
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Dexketoprofen Trometamol low dose, oral film-coated table, once
Dexketoprofen Trometamol high dose, oral film-coated table, once
Tramadol Hydrochloride low dose, oral film-coated table, once
Tramadol Hydrochloride high dose, oral film-coated table, once
Ibuprofen 400 mg, oral film-coated table, once
Placebo, oral film-coated table, once
Drug pages: Dexketoprofen · Tramadol
DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
Drug pages: Dexketoprofen · Tramadol
DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
Drug pages: Dexketoprofen · Tramadol
DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
Drug pages: Dexketoprofen · Tramadol
DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.
Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %
Time frame: 6 hours
Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.
Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %
Time frame: 4, 8 and 12 hours
Percentage of Patients Using Rescue Medication at 6 Hours
Percentage of patients using rescue medication at 6 hours post-dosing.
Time frame: Baseline to 6 hours
First patient in (screening) 23 Feb 2011, last patient out 14 Oct 2011. At 16 study centres in 6 European countries (Germany, Italy, Hungary, Poland, Spain and United Kingdom).
| Milestone | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 61 | 63 | 63 | 61 | 60 | 61 | 59 | 60 | 61 | 62 |
| Safety population | 61 | 63 | 63 | 61 | 60 | 61 | 59 | 60 | 61 | 62 |
| Itt (>= 1 assessment post randomization) | 60 | 62 | 63 | 61 | 60 | 60 | 59 | 59 | 60 | 62 |
| Completed | 61 | 62 | 62 | 60 | 60 | 61 | 58 | 60 | 61 | 62 |
| Not completed | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Electronic data capture failure | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %
| percentage of patients | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing. | 36.7 | 59.7 | 55.6 | 72.1 | 26.7 | 55.0 | 10.2 | 25.4 | 45.0 | 9.7 |
Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %
| percentage of patient | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| at 4 hours post-dose | 63.3 | 72.6 | 65.1 | 78.7 | 40.0 | 65.0 | 11.9 | 23.7 | 56.7 | 6.5 |
| at 8 hours post-dose | 21.7 | 48.4 | 44.4 | 54.1 | 16.7 | 31.7 | 6.8 | 20.3 | 33.3 | 6.5 |
| at 12 hours post-dose | 11.7 | 35.5 | 28.6 | 37.7 | 10.0 | 13.3 | 5.1 | 15.3 | 25.0 | 6.5 |
Percentage of patients using rescue medication at 6 hours post-dosing.
| percentage of patients | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Patients Using Rescue Medication at 6 Hours | 66.7 | 46.8 | 39.7 | 37.7 | 65.0 | 53.3 | 69.5 | 64.4 | 48.3 | 72.6 |
Collected over 10 ± 3 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | — | 0/61 (0%) | 7/61 (11.5%) |
| DKP-TRIS 12.5mg - TRAM.HCl 75mg | — | 0/63 (0%) | 9/63 (14.3%) |
| DKP-TRIS 25mg - TRAM.HCl 37.5mg | — | 0/63 (0%) | 6/63 (9.5%) |
| DKP-TRIS 25mg - TRAM.HCl 75mg | — | 0/61 (0%) | 10/61 (16.4%) |
| DKP-TRIS 12.5mg | — | 0/60 (0%) | 2/60 (3.3%) |
| DKP-TRIS 25mg | — | 0/61 (0%) | 4/61 (6.6%) |
| TRAM.HCl 37.5mg | — | 0/59 (0%) | 5/59 (8.5%) |
| TRAM.HCl 75mg | — | 1/60 (1.7%) | 14/60 (23.3%) |
| Ibuprofen 400mg | — | 0/61 (0%) | 5/61 (8.2%) |
| Placebo | — | 0/62 (0%) | 1/62 (1.6%) |
| Event | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/61 | 0/63 | 0/63 | 0/61 | 0/60 | 0/61 | 0/59 | 1/60 | 0/61 | 0/62 |
| Event | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/61 | 4/63 | 1/63 | 4/61 | 2/60 | 1/61 | 1/59 | 6/60 | 0/61 | 0/62 |
| VomitingGastrointestinal disorders | 3/61 | 4/63 | 3/63 | 5/61 | 0/60 | 2/61 | 0/59 | 5/60 | 2/61 | 0/62 |
| DizzinessNervous system disorders | 1/61 | 5/63 | 1/63 | 3/61 | 0/60 | 0/61 | 2/59 | 4/60 | 2/61 | 1/62 |
| HeadacheNervous system disorders | 0/61 | 1/63 | 2/63 | 0/61 | 0/60 | 0/61 | 3/59 | 2/60 | 1/61 | 0/62 |
| PyrexiaGeneral disorders | 3/61 | 0/63 | 0/63 | 3/61 | 0/60 | 2/61 | 1/59 | 3/60 | 1/61 | 0/62 |
| Age Continuous(years) | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 28.6 ± 7.64 | 26.9 ± 7.62 | 26.3 ± 7.33 | 27.3 ± 7.55 | 27.0 ± 9.85 | 26.9 ± 6.94 | 25.5 ± 7.15 | 27.8 ± 7.99 | 26.6 ± 6.48 | 26.1 ± 6.64 | 26.9 ± 7.56 |
| Sex: Female, Male(Participants) | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 35 | 39 | 36 | 34 | 36 | 44 | 38 | 28 | 41 | 33 | 364 |
| Male | 26 | 24 | 27 | 27 | 24 | 17 | 21 | 32 | 20 | 29 | 247 |
| BMI(kg/m^2) | DKP-TRIS 12.5mg - TRAM.HCl 37.5mg | DKP-TRIS 12.5mg - TRAM.HCl 75mg | DKP-TRIS 25mg - TRAM.HCl 37.5mg | DKP-TRIS 25mg - TRAM.HCl 75mg | DKP-TRIS 12.5mg | DKP-TRIS 25mg | TRAM.HCl 37.5mg | TRAM.HCl 75mg | Ibuprofen 400mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 23.7 ± 3.39 | 24.1 ± 3.69 | 23.0 ± 2.87 | 23.2 ± 3.19 | 23.6 ± 3.20 | 23.5 ± 3.30 | 23.0 ± 3.19 | 24.2 ± 3.08 | 22.4 ± 3.04 | 22.7 ± 2.80 | 23.3 ± 3.21 |
The record gives a start of Feb 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexketoprofen · Tramadol